Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Sorafenib vs placebo in treatment-naïve FLT3-ITD AML

Andrew Wei • 3 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Sorafenib

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the results of a Phase II study (ALLG AML M16) aiming to evaluate the efficacy a combined sorafenib and chemotherapy treatment in previously untreated FLT3-ITD acute myeloid leukemia (AML) patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrew Wei

New approaches to target TP53-mutated AML: the ADAPT trial
10:05
New approaches to target TP53-mutated AML: the ADAPT trial
Andrew Wei • 20 Sep 2026
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
18:47
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
Andrew Wei et al. • 20 Sep 2026
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Wei et al. • 19 Sep 2025
Current challenges in clinical genomics
Current challenges in clinical genomics
Andrew Wei et al. • 29 Sep 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals